Except for ER/PR−/HER2+ tumor subtypes, ER/PR/HER2− tumors, also called triple-negative breast cancer (TNBC), show aggressive behavior and poor outcome, with the highest mortality rate and recurrence, and are least likely to respond to hormone therapy. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.